ABSTRACT
Background: Dissemination and implementation (D&I) research is a key factor in the uptake and use of evidence-based cancer control interventions. National Cancer Institute (NCI)-designated cancer centers are ideal settings in which to further D&I knowledge. The purpose of this study was to summarize the characteristics of NCI-funded D&I science grants in the nation's cancer centers to understand the nature, extent, and opportunity for this key type of translational work. Methods: We used the National Institutes of Health Research Portfolio Online Reporting Tool to identify active NCI-funded grants in D&I science at NCI clinical cancer centers (n = 13) and comprehensive cancer centers (n = 51) as well as their academic affiliates. Active projects were eligible for inclusion if they 1) were awarded directly to an NCI cancer center or an academic or research affiliate, and 2) identified D&I content in the abstract. Portfolio data were collected in February 2021. Results: We identified 104 active NCI-funded D&I research or training grants across the 64 cancer centers; 57.8% of cancer centers had at least 1 NCI-funded D&I grant. Most awards (71.1%) were for research grants. Training grants constituted 29.1% of D&I-focused grants. Overall, 50.0% of grants (n = 52) concentrated on specific cancers. Almost two-thirds of grants (n = 68, 65.4%) had a stated health equity focus. Conclusions: More than one-half of NCI-designated cancer centers have active funding in D&I science, reflecting a substantial investment by NCI. There remains considerable room for further development, which would further support NCI's translational mission.
Subject(s)
Cancer Care Facilities/statistics & numerical data , Financing, Government/statistics & numerical data , Implementation Science , National Cancer Institute (U.S.) , Neoplasms , Translational Research, Biomedical/statistics & numerical data , Humans , Neoplasms/prevention & control , Translational Research, Biomedical/economics , United StatesABSTRACT
There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
Subject(s)
Cancer Care Facilities , Neoplasms/therapy , Quality of Health Care , Academies and Institutes/standards , Academies and Institutes/statistics & numerical data , Biomedical Research/organization & administration , Biomedical Research/standards , Biomedical Research/statistics & numerical data , Cancer Care Facilities/organization & administration , Cancer Care Facilities/statistics & numerical data , Cohort Studies , Europe/epidemiology , Humans , Medical Oncology/standards , Medical Oncology/statistics & numerical data , Neoplasms/epidemiology , Patient Care Team/organization & administration , Patient Care Team/standards , Patient Care Team/statistics & numerical data , Patient-Centered Care/organization & administration , Patient-Centered Care/standards , Patient-Centered Care/statistics & numerical data , Translational Research, Biomedical/methods , Translational Research, Biomedical/organization & administration , Translational Research, Biomedical/statistics & numerical dataABSTRACT
INTRODUCTION: The Accreditation Council for Graduate Medical Education provided guidelines, in 2013, regarding 13 clinical procedures pediatric residents should learn. Previous studies show that, when asked, general pediatricians (GPeds) self-report performing these procedures infrequently. When examined using the knowledge translation model, this low procedural performance frequency, especially by GPeds, may indicate a problem within the primary care landscape. METHODS: This was a descriptive study using the Partners For Kids, an accountable care organization, database to obtain how frequently each of the procedures was performed for a geographically representative sample of GPeds in central Ohio. RESULTS: A total of 296 physicians participated in Partners For Kids. Nearly one-third practiced for more than 15 years (n = 83, 28%) and one-third also lived in a rural region (n = 78, 26.4%). The most commonly billed procedure was administering immunizations (n = 79,292, 92.3%); the least was peripheral intravenous catheter placement (n = 2, 0.002%). Most procedures were completed in the office-based setting. DISCUSSION: General pediatricians in central Ohio do not frequently perform the 13 recommended procedures of Accreditation Council for Graduate Medical Education. Evaluation of this problem using the knowledge translation model shows that potential barriers could be inadequate training during or after residency or more likely that these procedures are not necessary in GPeds' current scope of practice. The next step should be to see, from the practitioner's perspective, what procedures are important to their daily practice. Adapting this knowledge to the local context will help target continuing medical education/continuing professional development interventions.
Subject(s)
Accreditation/methods , Methods , Pediatricians/standards , Accreditation/statistics & numerical data , Clinical Competence/standards , Clinical Competence/statistics & numerical data , Humans , Ohio , Organization and Administration , Pediatricians/statistics & numerical data , Translational Research, Biomedical/instrumentation , Translational Research, Biomedical/methods , Translational Research, Biomedical/statistics & numerical dataABSTRACT
BACKGROUND: With the rise of precision medicine efforts worldwide, our study objective was to describe and map the emerging precision medicine landscape. A Google search was conducted between June 19, 2017 to July 20, 2017 to examine how "precision medicine" and its analogous terminology were used to describe precision medicine efforts. Resulting web-pages were reviewed for geographic location, data type(s), program aim(s), sample size, duration, and the key search terms used and recorded in a database. Descriptive statistics were applied to quantify terminology used to describe specific precision medicine efforts. Qualitative data were analyzed for content and patterns. RESULTS: Of the 108 programs identified through our search, 84% collected only biospecimen(s) and, of those that collected at least two data types, 42% mentioned both Electronic Health Records (EHR) and biospecimen. Given the majority of efforts limited to biospecimen(s) use, genetic research seems to be prioritized in association with precision medicine. Roughly, 54% were found to collect two or more data types, which limits the output of information that may contribute to understanding of the interplay of genetic, lifestyle, and environmental factors. Over half were government-funded with roughly a third being industry-funded. Most initiatives were concentrated in the United States, Europe, and Asia. CONCLUSIONS: To our knowledge, this is the first study to map and qualify the global precision medicine landscape. Our findings reveal that precision medicine efforts range from large model cohort studies involving multidimensional, longitudinal data to biorepositories with a collection of blood samples. We present a spectrum where past, present, and future PM-like efforts can fall based on their scope and potential impact. If precision medicine is based on genes, lifestyle and environmental factors, we recommend programs claiming to be precision medicine initiatives to incorporate multidimensional data that can inform a holistic approach to healthcare.
Subject(s)
Electronic Health Records/statistics & numerical data , Genetics, Medical/methods , Precision Medicine/statistics & numerical data , Terminology as Topic , Translational Research, Biomedical/statistics & numerical data , Asia , Big Data , Blood Specimen Collection/methods , Europe , Gene-Environment Interaction , Humans , Life Style , United StatesABSTRACT
Translational research is redefined in this paper using a combination of methods in statistics and data science to enhance the understanding of outcomes and practice in occupational therapy. These new methods are applied, using larger data and smaller single-subject data, to a study in hippotherapy for children with developmental disabilities (DD). The Centers for Disease Control and Prevention estimates DD affects nearly 10 million children, aged 2-19, where diagnoses may be comorbid. Hippotherapy is defined here as a treatment strategy in occupational therapy using equine movement to achieve functional outcomes. Semiparametric ratio estimator (SPRE), a single-subject statistical and small data science model, is used to derive a "change point" indicating where the participant adapts to treatment, from which predictions are made. Data analyzed here is from an institutional review board approved pilot study using the Hippotherapy Evaluation and Assessment Tool measure, where outcomes are given separately for each of four measured domains and the total scores of each participant. Analysis with SPRE, using statistical methods to predict a "change point" and data science graphical interpretations of data, shows the translational comparisons between results from larger mean values and the very different results from smaller values for each HEAT domain in terms of relationships and statistical probabilities.
Subject(s)
Developmental Disabilities , Equine-Assisted Therapy , Occupational Therapy , Translational Research, Biomedical , Adolescent , Animals , Child , Child, Preschool , Female , Humans , Male , Pilot Projects , Translational Research, Biomedical/statistics & numerical data , Young AdultABSTRACT
BACKGROUND: Over the last 20 years, countries in sub Saharan Africa have made significant strides in the implementation of programs for HIV prevention, care and treatment. Despite, the significant progress made, many targets set by the United Nations have not been met. There remains a large gap between the ideal and what has been achieved. There are several operational issues that may be responsible for this gap, and these need to be addressed in order to achieve the targets. Therefore, the aim of this study was to identify gaps in the HIV prevention, care and treatment cascade, in a large district based HIV implementation program. We aimed to identify gaps that are amenable for evaluation using implementation science, in order to improve the delivery of HIV programs in rural Uganda. METHODS: We conducted key informant (KI) interviews with 60 district health officers and managers of HIV/AIDS clinics and organizations and 32 focus group discussions with exit clients seeking care and treatment for HIV in the 19 districts. The data analysis process was guided using a framework approach. The recordings were transcribed verbatim. Transcripts were read back and forth and codes generated based on the framework. RESULTS: Nine emerging themes that comprise the gaps were identified and these were referral mechanisms indicating several loop holes, low levels of integration of HIV/TB services, low uptake of services for PMTCT services by pregnant women, low coverage of services for most at risk populations (MARPs), poor HIV coordination structures in the districts, poor continuity in the delivery of pediatric HIV/AIDS services, limited community support for orphans and vulnerable (OVC's), inadequate home based care services and HIV services and support for discordant couples. The themes indicate there are plenty of gaps that need to be covered and have been ignored by current programs. CONCLUSIONS: Our study has identified several gaps and suggested several interventions that should be tested before large scale implementation. The implementation of these programs should be adequately evaluated in order to provide field evidence of effectiveness and replicability in similar areas.
Subject(s)
Acquired Immunodeficiency Syndrome/prevention & control , HIV Infections/prevention & control , Rural Health/statistics & numerical data , Translational Research, Biomedical/statistics & numerical data , Acquired Immunodeficiency Syndrome/therapy , Child , Community Health Services/methods , Community Health Services/statistics & numerical data , Delivery of Health Care, Integrated/methods , Delivery of Health Care, Integrated/statistics & numerical data , Female , Focus Groups , HIV Infections/therapy , Health Services Accessibility/statistics & numerical data , Humans , Male , Pregnancy , Qualitative Research , Rural Health/standards , Translational Research, Biomedical/methods , UgandaABSTRACT
It is widely accepted that more needs to be done to bring new, safe, and efficacious drugs to the market. Cardiovascular toxicity detected both in early drug discovery as well as in the clinic, is a major contributor to the high failure rate of new molecules. The growth of translational safety offers a promising approach to improve the probability of success for new molecules. Here we describe a cross-company initiative to determine the concordance between the conscious telemetered dog and phase I outcome for 3 cardiovascular parameters. The data indicate that, in the context of the methods applied in this analysis, the ability to detect compounds that affect the corrected QT interval (QTc) was good within the 10-30x exposure range but the predictive or detective value for heart rate and diastolic blood pressure was poor. These findings may highlight opportunities to refine both the animal and the clinical study designs, as well as refocusing the assessment of value of dog cardiovascular assessments beyond phase 1. This investigation has also highlighted key considerations for cross-company data sharing and presents a unique learning opportunity to improve future translational projects.
Subject(s)
Clinical Trials, Phase I as Topic/statistics & numerical data , Drug Evaluation, Preclinical/statistics & numerical data , Drug Industry/standards , Drug-Related Side Effects and Adverse Reactions/etiology , Translational Research, Biomedical/methods , Animals , Blood Pressure/drug effects , Cardiotoxicity , Clinical Trials, Phase I as Topic/methods , Clinical Trials, Phase I as Topic/standards , Dogs , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/standards , Drug-Related Side Effects and Adverse Reactions/physiopathology , Electrocardiography , Healthy Volunteers , Heart Rate/drug effects , Humans , Predictive Value of Tests , Sensitivity and Specificity , Telemetry , Translational Research, Biomedical/standards , Translational Research, Biomedical/statistics & numerical dataSubject(s)
Biomedical Research/standards , Drug Evaluation, Preclinical/standards , Neoplasms/drug therapy , Translational Research, Biomedical/statistics & numerical data , Animals , Cell Line, Tumor , Clinical Trials as Topic/statistics & numerical data , Humans , Mice , Neoplasms/genetics , Reproducibility of Results , Research Design/statistics & numerical data , Survival Analysis , Translational Research, Biomedical/standards , Translational Research, Biomedical/trends , Treatment FailureABSTRACT
Drug discovery for brain disorders is undergoing a period of upheaval. Faced with an empty drug pipeline and numerous failures of potential new drugs in clinical trials, many large pharmaceutical companies have been shrinking or even closing down their research divisions that focus on central nervous system (CNS) disorders. In this paper, we argue that many of the difficulties facing CNS drug discovery stem from a lack of robustness in pre-clinical (i.e., non-human animal) testing. There are two main sources for this lack of robustness. First, there is the lack of replicability of many results from the pre-clinical stage, which we argue is driven by a combination of publication bias and inappropriate selection of statistical and experimental designs. Second, there is the frequent failure to translate results in non-human animals to parallel results in humans in the clinic. This limitation can only be overcome by developing new behavioral tests for non-human animals that have predictive, construct, and etiological validity. Here, we present these translational difficulties as a "grand challenge" to researchers from comparative cognition, who are well positioned to provide new methods for testing behavior and cognition in non-human animals. These new experimental protocols will need to be both statistically robust and target behavioral and cognitive processes that allow for better connection with human CNS disorders. Our hope is that this downturn in industrial research may represent an opportunity to develop new protocols that will re-kindle the search for more effective and safer drugs for CNS disorders.